Cargando…

Current Progress in Cancer Treatment Using Nanomaterials

The pathological processes of cancer are complex. Current methods used for chemotherapy have various limitations, such as cytotoxicity, multi-drug resistance, stem-like cells growth, and lack of specificity. Several types of nanomaterials are used for cancer treatment. Nanomaterials 1–100 nm in size...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Ruirui, Zhang, Fangyuan, Peng, Yudong, Xie, Tian, Wang, Yi, Lan, Yin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9330335/
https://www.ncbi.nlm.nih.gov/pubmed/35912195
http://dx.doi.org/10.3389/fonc.2022.930125
_version_ 1784758135685120000
author Zhu, Ruirui
Zhang, Fangyuan
Peng, Yudong
Xie, Tian
Wang, Yi
Lan, Yin
author_facet Zhu, Ruirui
Zhang, Fangyuan
Peng, Yudong
Xie, Tian
Wang, Yi
Lan, Yin
author_sort Zhu, Ruirui
collection PubMed
description The pathological processes of cancer are complex. Current methods used for chemotherapy have various limitations, such as cytotoxicity, multi-drug resistance, stem-like cells growth, and lack of specificity. Several types of nanomaterials are used for cancer treatment. Nanomaterials 1–100 nm in size have special optical, magnetic, and electrical characteristics. Nanomaterials have been fabricated for cancer treatments to overcome cytotoxicity and low specificity, and improve drug capacity and bioavailability. Despite the increasing number of related studies, few nanodrugs have been approved for clinical use. To improve translation of these materials, studies of targeted drug delivery using nanocarriers are needed. Cytotoxicity, enhanced permeability and retention effects, and the protective role of the protein corona remain to be addressed. This mini-review summarizes new nanomaterials manufactured in studies and in clinical use, analyses current barriers preventing their translation to clinical use, and describes the effective application of nanomaterials in cancer treatment.
format Online
Article
Text
id pubmed-9330335
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-93303352022-07-29 Current Progress in Cancer Treatment Using Nanomaterials Zhu, Ruirui Zhang, Fangyuan Peng, Yudong Xie, Tian Wang, Yi Lan, Yin Front Oncol Oncology The pathological processes of cancer are complex. Current methods used for chemotherapy have various limitations, such as cytotoxicity, multi-drug resistance, stem-like cells growth, and lack of specificity. Several types of nanomaterials are used for cancer treatment. Nanomaterials 1–100 nm in size have special optical, magnetic, and electrical characteristics. Nanomaterials have been fabricated for cancer treatments to overcome cytotoxicity and low specificity, and improve drug capacity and bioavailability. Despite the increasing number of related studies, few nanodrugs have been approved for clinical use. To improve translation of these materials, studies of targeted drug delivery using nanocarriers are needed. Cytotoxicity, enhanced permeability and retention effects, and the protective role of the protein corona remain to be addressed. This mini-review summarizes new nanomaterials manufactured in studies and in clinical use, analyses current barriers preventing their translation to clinical use, and describes the effective application of nanomaterials in cancer treatment. Frontiers Media S.A. 2022-07-14 /pmc/articles/PMC9330335/ /pubmed/35912195 http://dx.doi.org/10.3389/fonc.2022.930125 Text en Copyright © 2022 Zhu, Zhang, Peng, Xie, Wang and Lan https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Zhu, Ruirui
Zhang, Fangyuan
Peng, Yudong
Xie, Tian
Wang, Yi
Lan, Yin
Current Progress in Cancer Treatment Using Nanomaterials
title Current Progress in Cancer Treatment Using Nanomaterials
title_full Current Progress in Cancer Treatment Using Nanomaterials
title_fullStr Current Progress in Cancer Treatment Using Nanomaterials
title_full_unstemmed Current Progress in Cancer Treatment Using Nanomaterials
title_short Current Progress in Cancer Treatment Using Nanomaterials
title_sort current progress in cancer treatment using nanomaterials
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9330335/
https://www.ncbi.nlm.nih.gov/pubmed/35912195
http://dx.doi.org/10.3389/fonc.2022.930125
work_keys_str_mv AT zhuruirui currentprogressincancertreatmentusingnanomaterials
AT zhangfangyuan currentprogressincancertreatmentusingnanomaterials
AT pengyudong currentprogressincancertreatmentusingnanomaterials
AT xietian currentprogressincancertreatmentusingnanomaterials
AT wangyi currentprogressincancertreatmentusingnanomaterials
AT lanyin currentprogressincancertreatmentusingnanomaterials